**Phenoxymethylpenicillin (Penicillin V) Monograph - Paediatric**

**Scope (Staff):** Clinical Staff – Medical, Nursing, Pharmacy

**Scope (Area):** Perth Children’s Hospital (PCH)

---

**DESCRIPTION**

Phenoxymethylpenicillin (also known as penicillin V) interferes with bacterial cell wall peptidoglycan synthesis by binding to penicillin binding proteins resulting in cell lysis.\(^1\-^4\)

**INDICATIONS AND RESTRICTIONS**

Phenoxymethylpenicillin is narrow spectrum penicillin mainly active against Gram-positive organisms and oral anaerobes but is inactivated by beta-lactamases.\(^2\)

The **treatment** indications for Phenoxymethylpenicillin are:

- Treatment of acute pharyngitis or tonsillitis due to *Streptococcus pyogenes*, to prevent acute rheumatic fever (ARF). Refer to [The 2020 Australian guideline for prevention, diagnosis and management of ARF and RHD (3rd Edition)](1, 5)
- Treatment of acute pharyngitis or tonsillitis due to *S. pyogenes* in children with moderate to severe pharyngitis.\(^2\)
- Scarlet fever.\(^2\)
- Treatment of ARF (if intolerant of intramuscular benzathine benzypenicillin).\(^5\)
- Dental infections (severe superficial infections).\(^2\)

The **prophylaxis** indications for Phenoxymethylpenicillin are:

- Secondary prophylaxis for ARF (if intolerant of intramuscular benzathine benzypenicillin).\(^5\)
- Prophylaxis of infection due to encapsulated organisms (e.g. pneumococcal infection) in asplenia, sickle cell anaemia, functional hyposplenia or post splenectomy.\(^2\)
- Prophylaxis following Haematopoietic stem cell transplantation (HSCT) until day 100, and no active Graft Versus Host Disease (GVHD) and all immunosuppressive agents ceased.\(^2, 3, 6\)

**Oral: Unrestricted (green) antibiotic**

This is not a restricted agent. Follow standard ChAMP guidelines where appropriate.

**CONTRAINDICATIONS**

Phenoxymethylpenicillin is generally contraindicated in patients with a history of high risk allergy to penicillins.\(^1, 2, 4, 6-8\)
**PRECAUTIONS**

Phenoxymethylpenicillin may be prescribed in selected patients with high risk allergy to another Beta-lactam sub-class (e.g. some cephalosporins, carbapenems) in discussion with immunology.

In patients with a previous low risk reaction to phenoxymethylpenicillin or another penicillin (delayed rash [>1hr after initial exposure] without mucosal or systemic involvement) the risk of subsequent reaction is low. Re-challenge may be acceptable in discussion with immunology.

**FORMULATIONS**

Available at PCH:
- 250mg tablets and capsules
- 50mg/mL powder for suspension

Other formulations available:
- 25mg/mL powder for suspension
- 30mg/mL suspension
- 250mg and 500mg tablets/capsules (multiple generic brands)

**DOSAGE**

- The doses listed below fall within the standard range.
- Higher doses may be prescribed for certain situations in consultation with an infectious diseases or clinical microbiology consultant.

**Neonates (< 1 month of age):**
Please refer to Neonatal Medication Protocols

**Children:**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of acute pharyngitis or tonsillitis due to <em>S. pyogenes</em> (including scarlet fever)</td>
<td>All children: 15mg/kg/dose (to a maximum of 500mg) 12 hourly for 10 days.&lt;sup&gt;1, 2, 5, 8&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Note:</strong> Antibiotics are not indicated for mild tonsillitis in children not at risk of ARF.&lt;sup&gt;1, 8&lt;/sup&gt;</td>
<td></td>
</tr>
</tbody>
</table>
| Treatment of ARF (if intolerant of intramuscular benzathine benzylpenicillin) | Child 1 month – 12 years: 250mg/dose twice daily for 10 days<sup>5, 6</sup>  
Child 12 – 18 years: 500mg/dose twice daily for 10 days<sup>5, 8</sup> |
| Dental infections (severe superficial infections) | All children: 12.5mg/kg/dose (to a maximum of 500mg) four times a day for 5 days.<sup>8, 9</sup> |
### Prophylaxis:

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dose</th>
</tr>
</thead>
</table>
| Secondary prophylaxis for ARF                   | **Child 1 month – 18 years:** 250mg/dose twice daily for 10 years.  
(1, 3, 5)                                       |

**Note:** IM Benzathine benzylpenicillin is preferred for treatment and prophylaxis of ARF/Rheumatic Heart Disease (RHD) due to improved efficacy and patient compliance.  
(2, 5, 8)

Prophylaxis in asplenia, sickle cell anaemia, functional hyposplenia or post splenectomy

| Child <1 year old:                           | 62.5mg/dose twice daily. (2) |
| Child 1-5 years old:                         | 125mg/dose twice daily. (2)  |
| Children ≥ 5 old:                            | 250mg/dose twice daily. (2, 6) |

Prophylaxis following Haematopoietic stem cell transplantation (HSCT)

| Child <1 year old:                           | 62.5mg/dose twice daily. (2) |
| Child 1-5 years old:                         | 125mg/dose twice daily. (2)  |
| Children ≥ 5 old:                            | 250mg/dose twice daily. (2, 6) |

Treatment should be continued until day +100, and no active GVHD and all immunosuppressive agents have been ceased

### DOSAGE ADJUSTMENT

- **Dosage adjustment required in renal impairment:**
  - No dosage adjustment is required in renal impairment, however the half-life may be prolonged in significant renal impairment.  
(1, 3, 4)  
- The potassium content of the preparation should be considered in patients with severe renal impairment.  
(7)

- **Dosage adjustment required in hepatic impairment:**
  - There are no specific recommendations for dosage adjustment in patients with hepatic impairment. It appears that no dose adjustment is necessary.  
(3)

### RECONSTITUTION

**Oral powder for suspension 50mg/mL**

Reconstitute the phenoxymethylpenicillin as per the product information with water as follows: Tap bottle until all the powder flows freely, add the total volume of water for reconstitution and shake vigorously to suspend the powder. Store the reconstituted suspension in a refrigerator between 2°C and 8°C and discard any remaining suspension after 10 days.
<table>
<thead>
<tr>
<th><strong>ADMINISTRATION</strong></th>
<th>Phenoxymethylpenicillin may be given without regard to food, however absorption may be slightly higher if administered on an empty stomach.(^1)(^3)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MONITORING</strong></td>
<td>Renal, hepatic and haematological function should be monitored with prolonged therapy (i.e. longer than 10 days).(^1)(^4)</td>
</tr>
</tbody>
</table>
| **ADVERSE EFFECTS** | **Common:** diarrhoea, nausea, vomiting, *Clostridium difficile* associated disease, immunological reactions (rash, erythema, urticaria, contact dermatitis, fever, angioedema, bronchospasm, interstitial nephritis, haemolytic anaemia, eosinophilia, serum sickness-like syndrome, exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis).\(^1\)\(^7\)  
**Rare:** allergy, black tongue, electrolyte disturbances, neurotoxicity (with high dose e.g. drowsiness, hallucinations, coma, seizures), bleeding, blood dyscrasias (e.g. thrombocytopenia).\(^1\)\(^7\) |
| **COMPATIBLE FLUIDS** | Not applicable |
| **STORAGE**       | 50mg/mL oral powder for suspension:  
- The 50mg/mL powder for suspension should be stored at less than 25°C prior to reconstitution.  
- Once reconstituted, the resultant suspension should be refrigerated between 2 and 8°C.\(^7\)  
- Refer to packaging for storage conditions of alternative brands and strengths.  
**Tablets and capsules:**  
- Tablets and capsules should be stored at less than 30°C.\(^7\) |
| **INTERACTIONS**  | **Phenoxymethylpenicillin has drug interactions; please consult PCH approved references (e.g. Clinical Pharmacology), your ward pharmacist or Pharmacy on extension 63546 for more information**  
- Phenoxymethylpenicillin increases the toxicity of methotrexate by reduction of excretion, monitor closely.\(^1\)\(^3\)\(^7\)  
- Tetracycline antibiotics (e.g. doxycycline, minocycline and tetracycline) may reduce the effect of phenoxymethylpenicillin.\(^3\)\(^4\) |
| **COMMENTS**      | - To access the Manufacturer SDS for this product, use the following link to ChemAlert. |

**Manufacturer Safety Data Sheet (SDS)**
**Please note: The information contained in this guideline is to assist with the preparation and administration of phenoxymethylpenicillin (penicillin V). Any variations to the doses recommended should be clarified with the prescriber prior to administration**

### Related internal policies, procedures and guidelines

- Antimicrobial Stewardship Policy
- ChAMP Empiric Guidelines
- KEMH Neonatal Medication Protocols

### References

Phenoxymethylpenicillin (Penicillin V)
Monograph

This document can be made available in alternative formats on request for a person with a disability.

<table>
<thead>
<tr>
<th>File Path:</th>
<th>W:\Safety &amp; Quality\CAHS\CLOVERS MEDICAL Pharmacy\Procedures Protocols and Guidelines\ChAMP\PDFs\Monographs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Document Owner:</td>
<td>Head of Department – Infectious Diseases</td>
</tr>
<tr>
<td>Reviewer / Team:</td>
<td>Children's Antimicrobial Management Program Pharmacist</td>
</tr>
<tr>
<td>Date First Issued:</td>
<td>September 2015</td>
</tr>
<tr>
<td>Amendment Dates:</td>
<td>September 2018</td>
</tr>
<tr>
<td>Last Reviewed:</td>
<td>May 2020</td>
</tr>
<tr>
<td>Next Review Date:</td>
<td>May 2023</td>
</tr>
<tr>
<td>Approved by:</td>
<td>Drug and Therapeutics Committee</td>
</tr>
<tr>
<td>Date:</td>
<td>June 2020</td>
</tr>
<tr>
<td>Endorsed by:</td>
<td>Chair, Drug and Therapeutics Committee</td>
</tr>
<tr>
<td>Date:</td>
<td>June 2020</td>
</tr>
</tbody>
</table>
| Standards Applicable: | NSQHS Standards: 📈
NSMHS: N/A
Child Safe Standards: N/A |

Printed or personally saved electronic copies of this document are considered uncontrolled.